Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adult

Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Iii HLTwigg, Weiden M, Valentine F, et al. "Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects." J. Infect. Dis.. 2008;197(1):109-16.
Palmer S, Boltz V, Martinson N, et al. "Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission." Proc. Natl. Acad. Sci. U.S.A.. 2006;103(18):7094-9.
Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.
Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. "Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084." AIDS Patient Care STDS. 2008;22(1):29-40.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Dooley KE, Park J-G, Swindells S, et al. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J. Acquir. Immune Defic. Syndr.. 2012;59(5):455-62.
Boswell KL, Paris R, Boritz E, et al. "Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection." PLoS Pathog.. 2014;10(1):e1003853.
Krishnan S, Schouten JT, Atkinson B, et al. "Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2012;61(3):381-9.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Shikuma CM, Yang Y, Glesby MJ, et al. "Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)." J. Acquir. Immune Defic. Syndr.. 2007;44(5):540-50.
Overton ET, Kitch D, Benson CA, et al. "Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death." Clin. Infect. Dis.. 2013;56(10):1471-9.
Dubé MP, Komarow L, Fichtenbaum CJ, et al. "Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation." Clin. Infect. Dis.. 2015;61(5):840-9.
Ribaudo HJ, Benson CA, Zheng Y, et al. "No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT." Clin. Infect. Dis.. 2011;52(7):929-40.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Demeter LM, Degruttola V, Lustgarten S, et al. "Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience." HIV Clin Trials. 2008;9(1):11-25.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.

Pages